May 20, 2021

Dr. Harriet Feilotter appointed as Director of the Ontario Molecular Pathology Research Network

Dr. Harriet Feilotter.

An announcement from Dr. Lincoln Stein, Head, Adaptive Oncology, OICR

I am pleased to announce the appointment of Dr. Harriet Feilotter as Director of the Ontario Molecular Pathology Research Network (OMPRN).

Feilotter has worked extensively with both OMPRN and the Ontario Institute for Cancer Research (OICR) over many years, with her expertise and leadership in molecular pathology, genetics, targeted biomarkers and informatics being critical to the success of both organizations.

As Director of OMPRN, Feilotter will provide scientific leadership for a province-wide network of pathologists and laboratory scientists collaborating to carry out high-quality cancer research with a clear potential for clinical impact, as well as bringing new educational and mentoring initiatives forward in this space. Working with other OICR programs and networks she will help to foster collaboration within the Institute and across the province, with a goal of further strengthening academic pathology across Ontario.

Feilotter takes over the role as Director of OMPRN from Dr. David LeBrun, who was OMPRN’s founding director. I would like to thank LeBrun for his vision and leadership of OMPRN as well as his expertise in building the Network over the past five years. 

At the same time, Feilotter is being appointed to the role of Lead, Clinical Implementation at OICR. This formalizes Feilotter’s existing role in working with OICR leadership to provide clinical genetics expertise to support OICR’s Ontario Pathway Towards Innovation in Cancer Care (OPTICC) project, and working with stakeholders such as Cancer Care Ontario/Ontario Health, the Ontario Ministry of Health and industry partners to promote the implementation of cancer innovations within the healthcare system.

Feilotter is currently also a Professor in the Department of Pathology and Molecular Medicine at Queen’s University, Director of the Molecular Genetics Laboratory at Kingston Health Sciences Centre and Chair of the Molecular Oncology Advisory Committee at Cancer Care Ontario/Ontario Health. Feilotter will remain based in Kingston but work with and provide support for researchers across the province.

“I am excited to be deepening my involvement with OMPRN as Director and to have the opportunity to build upon the Network’s success thus far. There are great opportunities before us in Ontario in molecular pathology. OMPRN will continue to strengthen our community of researchers and collaborate to bring improved solutions to patients.” — Dr. Harriet Feilotter.